Du är här


ContextVision AB : ContextVision AB presents Q2 2015 report

ContextVision continues positive sales developmentContextVision AB (OSE: COV), the medical imaging software company, today
announced its second quarter and first half 2015 financial results.
ContextVision continues its positive sales development. Revenues in the
second quarter were 15 per cent higher than in the corresponding quarter last
year and at par with the strong first quarter 2015.

As expected, the significant increase in R&D activities influenced the
operating result in the quarter, demonstrating that ContextVision is well
underway in expanding its technology platform.

ContextVision's sales in the second quarter were SEK 18.1 million, compared to
SEK 15.8 million in last year's second quarter. The operating result ended at
SEK 1.0 million against SEK 2.6 million last year, reflecting an increase in
non-capitalized R&D costs. The operating margin for this year's second
quarter was 5.4 percent. However the operating margin for our core business
was over 16%.

For the first half 2015, sales were SEK 36.4 million, compared to SEK 33.4
million last year. Operating result for the first half was SEK 2.9 million,
vs SEK 4.5 million for the first six months of 2014.

ContextVision had particularly strong sales in Europe in the second quarter,
while the U.S. sales figures also were boosted by the strong USD. The first
half figures reflect both a positive sales development in the existing
customer base as well as an extraordinarily high number of new customers. The
most sophisticated ultrasound segments remain ContextVisions main growth

"The second quarter confirms ContextVision's ability to uphold sales growth
and profitability while investing aggressively in the development of new
technology," said CEO Anita Tollstadius.

From 2015 the Company has significantly increased its R&D activities, in order
to develop new technology for its existing market as well as preparing for
entry in new markets. ContextVision is currently the industry leader in
sophisticated software for enhancement and analysis of medical images, and is
preparing for expansion into the emerging digital pathology market. The new
technology is expected to position ContextVision in a new market ten times
the size of its current available market by 2018.

About ContextVision

ContextVision's cutting edge technology helps doctors interpret medical
images, a crucial basis for accurate diagnosis and treatment. ContextVision
provides state-of-the-art medical image analysis and enhancement software to
equipment manufacturers worldwide. The company started out as an industry
pioneer more than 30 years ago, and is today the global leader within
specialized software for 2D/3D/4D Ultrasound, MRI, X-Ray, Mammography and CT.
The company is investing heavily in R&D in order to expand its technology
platform. ContextVision is based in Sweden and listed on the Oslo Stock
Exchange under the ticker COV. For more information, please

For further information, please contact ContextVision's CEO, Anita
Tollstadius, telephone +46 70 337 3026.

ContextVision Q2 2015 report


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ContextVision AB via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.